Alogliptin

Routes
Oral (PO)
Half-Life (t½)
PO: 21h
Formula
C18H21N5O2
Molecular Weight
339.39 g/mol
PubChem CID
11450633
Aliases
Nesina

Pharmacological Mechanism

DPP-4 inhibitor — same mechanism as sitagliptin, linagliptin, saxagliptin (raises endogenous GLP-1 + GIP). Renal dose adjustment needed. Heart failure signal in EXAMINE trial led to FDA boxed warning.

Half-Life & Elimination Curve (PO: 21h)

100%50%25%12.5%0%0h0×t½21h1×t½42h2×t½63h3×t½3.5d4×t½4.4d5×t½0×t½ (0h): 100% remaining (~32.9 µg/L)1×t½ (21h): 50% remaining (~16.5 µg/L)2×t½ (42h): 25% remaining (~8.23 µg/L)3×t½ (63h): 12.5% remaining (~4.11 µg/L)4×t½ (3.5d): 6.3% remaining (~2.06 µg/L)5×t½ (4.4d): 3.1% remaining (~1.03 µg/L)
Plasma (PO)t½ Decay (21h)Effect Site (ke0)
  • 0×t½0h100% (32.9 µg/L)
  • 1×t½21h50% (16.5 µg/L)
  • 2×t½42h25% (8.23 µg/L)
  • 3×t½63h12.5% (4.11 µg/L)
  • 4×t½3.5d6.3% (2.06 µg/L)
  • 5×t½4.4d3.1% (1.03 µg/L)
Elimination t½21h (PO)
Rate Constant (ke)0.033 h⁻¹
Time to Peak (Tmax)5.12h
Est. Peak (Cmax)32.9 µg/L
Clearance (CL)13.8 L/h
97% Washout (5×t½)4.4d

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References